Small vs Large Vessel Vasculitis: Treatment Differences

Small vessel vasculitis and large vessel vasculitis are treated very differently. Small vessel disease — conditions like granulomatosis with polyangiitis and microscopic polyangiitis — typically requires powerful immunosuppressants that target antibody-producing cells. Large vessel disease — giant cell arteritis and Takayasu arteritis — is usually managed with corticosteroids first, with newer biologics increasingly used to reduce long-term steroid exposure. Getting the category right matters because the wrong treatment approach can mean undercontrolled disease in one case or unnecessary toxicity in another.

This explainer draws on published research from five rheumatologists in the Convene directory whose work spans both sides of the spectrum: Leonard Calabrese, DO, at Cleveland Clinic, who co-authored the landmark 1990 ACR classification criteria that defined how these conditions are categorized [3][4]; Carol Langford, MD, also at Cleveland Clinic, whose published work includes the RAVE trial comparing rituximab to cyclophosphamide for ANCA-associated vasculitis [1] and the MIRRA trial establishing mepolizumab for eosinophilic granulomatosis with polyangiitis [6]; Kenneth Warrington, MD, chair of rheumatology at Mayo Clinic, who has published extensively on large vessel giant cell arteritis cohorts and Takayasu arteritis natural history [5]; and Eli Miloslavsky, MD, and Sebastian Unizony, MD, both at Massachusetts General Hospital, whose research addresses remission induction for ANCA-associated vasculitis [7][8] and the GiACTA tocilizumab trial for giant cell arteritis [2], respectively.

What the categories mean

Vasculitis is inflammation of blood vessel walls. The "small" and "large" labels refer to which size of vessel is predominantly affected, which in turn tells your rheumatologist a great deal about what is likely happening and what to do about it.

Small vessel vasculitis affects capillaries, venules, and small arterioles. When these tiny vessels become inflamed, the damage shows up in the kidneys, lungs, sinuses, and skin. The most common forms are ANCA-associated vasculitides: granulomatosis with polyangiitis (GPA, formerly Wegener's), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss syndrome). The "ANCA" in that name refers to anti-neutrophil cytoplasmic antibodies — proteins that trigger the immune attack.

Large vessel vasculitis affects the aorta and its major branches. Giant cell arteritis (GCA) is the most common form in adults over 50. It inflames the arteries that supply the scalp, jaw, and eyes — which is why sudden vision loss is one of its most feared complications. Takayasu arteritis is a rarer form that tends to affect younger women and can narrow blood vessels to the point of affecting circulation to the arms or abdomen.

The ACR's 1990 classification criteria, co-developed by research from Calabrese's group, formalized these distinctions and gave physicians a common language for diagnosing GCA, Takayasu, GPA, and polyarteritis nodosa [3][4]. Those criteria remain foundational even as newer classification work has refined them.

At a glance

How small vessel vasculitis is treated

For ANCA-associated small vessel vasculitis, treatment is split into two phases: induction (stopping the initial flare) and maintenance (preventing relapse).

Induction. The 2010 RAVE trial — co-authored by Langford — directly compared rituximab, a biologic that depletes B cells, to cyclophosphamide as induction therapy in 197 patients with severe ANCA-associated vasculitis [1]. Rituximab was non-inferior to cyclophosphamide for inducing remission overall, and it was actually superior in patients with relapsing disease. This shifted practice: rituximab became a preferred induction option for many patients, particularly for GPA and for those in whom cyclophosphamide's toxicity is a concern (bladder damage, infection risk, reduced fertility in younger patients).

High-dose corticosteroids are still used alongside rituximab or cyclophosphamide during induction. A 2013 NEJM trial examining different induction regimens found that the combination approach of adding plasma exchange to immunosuppression benefited patients with severe kidney disease, though subsequent trials have refined understanding of which patients gain the most from this [7].

Maintenance. Once remission is achieved, the goal shifts to staying in remission on the lowest possible drug burden. Rituximab, given on a scheduled maintenance schedule, has become a favored option over azathioprine in many centers. The 2020 BMJ review co-authored by Miloslavsky summarizes the current evidence base for this two-phase framework [8].

EGPA, the eosinophil-driven form, recently gained a more targeted option. A 2017 NEJM trial of mepolizumab — an antibody that blocks IL-5, the cytokine that drives eosinophil production — showed that patients receiving mepolizumab were significantly more likely to achieve remission and spend more time in remission than those on placebo, and required lower corticosteroid doses [6]. This was an important development because EGPA patients often struggle with steroid side effects from years of treatment.

How large vessel vasculitis is treated

Large vessel disease centers on a different biology: granulomatous inflammation driven by T cells and macrophages rather than ANCA antibodies. The treatment history is older and, until recently, more limited.

Corticosteroids are still the foundation. For GCA, high-dose prednisone (typically 40–60 mg daily) is started immediately on diagnosis — often even before the biopsy confirms it, because vision loss can occur within hours of the first symptoms. The goal is to extinguish the inflammation fast. Most patients see rapid symptom relief.

The problem is the taper. Warrington's large vessel GCA cohort study found that patients with GCA affecting the aorta and its branches had higher relapse rates and greater steroid requirements than patients with typical cranial GCA [5]. Getting people off prednisone without triggering a relapse is hard, and many patients end up on years of steroids with all the attendant risks (diabetes, osteoporosis, infection).

Tocilizumab changed the picture. The GiACTA trial, the pivotal study published in NEJM 2017 with Unizony as a co-investigator, randomized 251 patients with GCA to weekly or every-other-week tocilizumab plus a 26-week prednisone taper, or to placebo plus either a 26-week or 52-week prednisone taper [2]. At 52 weeks, 56% of patients in the weekly tocilizumab group achieved sustained remission compared to 14% to 18% in the placebo groups. Tocilizumab blocks the IL-6 receptor, an inflammatory pathway that appears particularly active in giant cell arteritis. The FDA approved tocilizumab (Actemra) for GCA in 2017 — the first approved treatment beyond corticosteroids for this condition.

For Takayasu arteritis, treatment is less standardized. Most guidelines recommend corticosteroids as first-line therapy, with methotrexate or azathioprine as steroid-sparing agents. Biologics including tocilizumab and TNF inhibitors are used in refractory cases, though trial evidence is thinner than for GCA.

What the classification criteria mean for you

A diagnosis of vasculitis is not enough information to guide treatment. Your rheumatologist needs to determine which category and which specific condition you have, because the treatment paths diverge quickly.

For patients with ANCA antibodies and kidney or lung involvement, the workup will focus on distinguishing GPA from MPA and determining severity — that affects whether rituximab or cyclophosphamide is used and whether plasma exchange is added.

For patients over 50 with headaches, jaw pain, scalp tenderness, or sudden visual changes, GCA needs to be ruled out urgently. The standard diagnostic test is a temporal artery biopsy, though ultrasound and MRI are increasingly used. Treatment often starts before the biopsy result comes back.

Takayasu arteritis, by contrast, typically presents in women under 40 with vascular symptoms — arm claudication (fatigue or pain with arm use), bruits (blood flow sounds your doctor hears with a stethoscope), or elevated inflammatory markers. Imaging of the aorta and its branches is usually needed.

Monitoring differences

Because small vessel vasculitis is driven by ANCA antibodies, ANCA levels can serve as a monitoring tool, though imperfectly. A rising ANCA titer after remission may predict relapse, but many patients relapse with stable ANCA levels, and some do not relapse despite rising titers. Kidney function and urinalysis (checking for blood or protein in the urine) are checked regularly because glomerulonephritis — kidney inflammation — can be silent until it is advanced.

Large vessel vasculitis monitoring relies more on inflammatory markers like ESR and CRP, along with imaging. Repeat vascular imaging (CTA, PET-CT, or MRI) may be used to assess whether the arterial inflammation is controlled or whether stenosis (vessel narrowing) is progressing. ESR and CRP can look normal in patients with ongoing vascular damage under tocilizumab, which itself suppresses these markers — a limitation your rheumatologist will account for.

Questions to ask your rheumatologist

• Which specific type of vasculitis do I have, and which size of vessel is primarily involved?
• Are my ANCA antibodies positive, and if so, which type — PR3 or MPO? How does that affect relapse risk?
• For small vessel disease: should I start with rituximab or cyclophosphamide, and what are the reasons to prefer one over the other in my situation?
• For GCA: should I start tocilizumab alongside my prednisone, and how does that change the steroid taper plan?
• What warning symptoms should prompt me to call you right away?
• If I am on rituximab, how often should I get B-cell counts checked?

The bottom line

Small vessel vasculitis and large vessel vasculitis look different, behave differently, and respond to different drugs. ANCA-associated small vessel disease is treated with rituximab or cyclophosphamide to induce remission, followed by long-term maintenance to prevent relapse — a framework supported by landmark trials including RAVE [1] and RITAZAREM. Large vessel disease, particularly GCA, is treated with corticosteroids and increasingly with tocilizumab, which the GiACTA trial showed can help patients achieve sustained remission with substantially lower steroid exposure [2]. Getting a precise diagnosis and matching the treatment to the correct category is the work of a specialist — and why vasculitis, despite being rare, is treated by dedicated rheumatologists rather than generalists.